Patrick Daly

DocwireNews

Researchers, led by Vasile Musteata, MD, PhD, MPH, conducted an observational cohort study to characterize treatment options and epidemiological, clinical, and laboratory features of <a href="https://medlineplus.gov/ency/article/000532.htm" target="_blank" rel="noopener">chronic lymphocytic leukemia</a> (CLL), the most common type of leukemia in Western Europe and North America.Their findings, which were reported at the 2023 Society of Hematologic Oncology Annual Meeting, suggested that CLL was most common in individuals from urban areas who are male and over 55 years of age.<h1>Chronic Lymphocytic Leukemia More Prevalent in Older, Urban Males</h1>The study reviewed 110 patients with CLL who were treated at the Institute of Oncology of Moldova between 2015 and 2022. The most common antineoplastic therapies patients received were chlorambucil and rituximab as monotherapies and , R-COP, and rituximab, fludarabine, and cyclophosphamide (RFC).Of the total cohort, 59 (53.64%) newly diagnosed patients were from urban areas. The most prevalent age ranges were 65 to 74 years (n=38; 34%) and 55 to 64 years (n=41; 37%), and males had a higher incidence (n=65; 59.3%) compared with females (n=45; 40.7%; P&lt;.05). Secondary conditions that developed included autoimmune thrombocytopenia in 23 (21.81%) patients and autoimmune hemolytic anemia in 28 (24.45%).Lastly, on the Binet staging system, 70 (63%) patients were diagnosed with Stage A and 39 (35%) were diagnosed with Stage B. Authors noted 5-year overall survival (OS) was higher (P&lt;.05) in patients with Stage B (80.33%) versus those with Stage C (66.67%). RFC had a complete response rate of (88.89%) and 5-year OS (84.35%).In closing, the authors noted that the &ldquo;RFC regimen proved to be the most efficient in terms of complete response rate and OS.&rdquo;Related: <a href="https://docwirenews.com/post/difference-in-anxiety-levels-between-oral-intravenous-treatment-in-patients-with-cll">Difference in Anxiety Levels Between Oral, Intravenous Treatment in Patients With CLL</a>

Kaitlyn Kosko

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

HER2 Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Jordana Jampel

Annual US Measles Cases Top 1,000, Worst Year Since Elimination

Infectious Disease

Latest News

Defining Disease Features, Treatment Options in Patients With CLL

SOHO 2023

Authors characterizing disease features and treatment options in patients with CLL found the RFC regimen appeared to be most effective for overall survival and response.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe